A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir in Patients With Locally Advanced Pancreatic Cancer

Trial Profile

A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir in Patients With Locally Advanced Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Oregovomab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Nelfinavir; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Status changed to discontinued due to the replacement of gemcitabine/ leucovorin/ Fluorouracil (GEM/LV/FU) by FOLFIRINOX and GEM/abraxane as standard of care for pancreatic adenocarcinoma as reported by results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2018 Results presented in an OncoQuest media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top